Head to Head Survey: Bonk (BNKK) versus Its Competitors

Bonk (NASDAQ:BNKK) is one of 343 publicly-traded companies in the “Financial Services” industry, but how does it contrast to its rivals? We will compare Bonk to related businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, risk, earnings and dividends.

Analyst Ratings

This is a summary of recent ratings and target prices for Bonk and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bonk	1	0	0	0	1.00
Bonk Competitors	1893	6728	11416	414	2.51

As a group, “Financial Services” companies have a potential upside of 3.72%. Given Bonk’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Bonk has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

12.6% of Bonk shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Financial Services” companies are owned by institutional investors. 51.6% of Bonk shares are owned by insiders. Comparatively, 22.0% of shares of all “Financial Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bonk and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bonk	-952.21%	-137.47%	-122.67%
Bonk Competitors	-407.42%	-21.88%	-5.62%

Risk and Volatility

Bonk has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Bonk’s rivals have a beta of 2.27, suggesting that their average stock price is 127% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bonk and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bonk	$2.12 million	-$68.19 million	-0.38
Bonk Competitors	$6.32 billion	$1.08 billion	9.19

Bonk’s rivals have higher revenue and earnings than Bonk. Bonk is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Bonk rivals beat Bonk on 12 of the 13 factors compared.

Bonk Company Profile

Safety Shot, Inc., a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. in September 2023. The company was incorporated in 2018 and is headquartered in Jupiter, Florida.